Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Michael C Heinrich"'
Autor:
Ting-lei Gu, Julie Nardone, Yi Wang, Marc Loriaux, Judit Villén, Sean Beausoleil, Meghan Tucker, Jon Kornhauser, Jianmin Ren, Joan MacNeill, Steven P Gygi, Brian J Druker, Michael C Heinrich, John Rush, Roberto D Polakiewicz
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e19169 (2011)
Activating mutations of FMS-like tyrosine kinase-3 (FLT3) are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 is therefore an attractive drug target. However, the molecular mechanisms by which FLT3 mutations lead to cel
Externí odkaz:
https://doaj.org/article/1023d0cf89bb45dc84d23254aa8bce3c
Publikováno v:
Leukemia Research Reports, Vol 21, Iss , Pp 100409- (2024)
Background: Systemic mastocytosis is a rare hematologic malignancy that leads to the accumulation of neoplastic mast cells in the bone marrow, visceral organs, and skin. Mutations in the receptor tyrosine kinase, KIT are seen in most patients with sy
Externí odkaz:
https://doaj.org/article/95e4a68de6c94be7908fd21089f7d09c
Autor:
Maria A. Pantaleo, Michael C. Heinrich, Antoine Italiano, Claudia Valverde, Patrick Schöffski, Giovanni Grignani, Anna K. L. Reyners, Sebastian Bauer, Peter Reichardt, Daniel Stark, Ghimja Berhanu, Ulrike Brandt, Tommaso Stefanelli, Hans Gelderblom
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidy
Externí odkaz:
https://doaj.org/article/2f1e77cece464909a2d9a3ecf8c75f78
Publikováno v:
Drugs
Prior to the early 2000s, patients with advanced gastrointestinal stromal tumors (GIST) had very poor prognoses owing to a lack of effective therapies. The development of tyrosine kinase inhibitors at the turn of the century significantly improved th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38a02ac08542ee00f2e8bf75c759d12
https://doi.org/10.1007/s40265-022-01820-1
https://doi.org/10.1007/s40265-022-01820-1
Autor:
Tony J. Zheng, Iván Parra-Izquierdo, Stéphanie E. Reitsma, Michael C. Heinrich, Mark K. Larson, Joseph J. Shatzel, Joseph E. Aslan, Owen J. T. McCarty
Publikováno v:
American Journal of Physiology-Cell Physiology. 323:C1231-C1250
Tyrosine kinase inhibitors (TKIs) have emerged as a promising class of target-directed, small molecule inhibitors used to treat hematologic malignancies, inflammatory diseases, and autoimmune disorders. Recently, TKIs have also gained interest as pot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d09662577e77e2d89a0459109050391
https://doi.org/10.1152/ajpcell.00040.2022
https://doi.org/10.1152/ajpcell.00040.2022
Autor:
Michael J. Mauro, Timothy P. Hughes, Dong-Wook Kim, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gómez-García de Soria, Philipp le Coutre, Francois-Xavier Mahon, Jeroen J. W. M. Janssen, Michael Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang
Publikováno v:
Mauro, M J, Hughes, T P, Kim, D-W, Rea, D, Cortes, J E, Hochhaus, A, Sasaki, K, Breccia, M, Talpaz, M, Ottmann, O, Minami, H, Goh, Y T, DeAngelo, D J, Heinrich, M C, Gómez-García de Soria, V, le Coutre, P, Mahon, F-X, Janssen, J J W M, Deininger, M, Shanmuganathan, N, Geyer, M B, Cacciatore, S, Polydoros, F, Agrawal, N, Hoch, M & Lang, F 2023, ' Asciminib monotherapy in patients with CML-CP without BCR : :ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results ', Leukemia, vol. 37, no. 5, pp. 1048-1059 . https://doi.org/10.1038/s41375-023-01860-w
Leukemia, 37(5), 1048-1059. Nature Publishing Group
Leukemia, 37(5), 1048-1059. Nature Publishing Group
Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of a phase 1, open-lab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437d3c00079171293194868f1b37fa7b
https://research.vumc.nl/en/publications/6d526334-4128-4e79-a87b-30d3fb304c73
https://research.vumc.nl/en/publications/6d526334-4128-4e79-a87b-30d3fb304c73
Autor:
Michael C. Heinrich, Ajia Town, Carol Beadling, Diana J. Griffith, Janice Patterson, Lillian R. Klug, Alison C. Macleod
Figure S1: HMC1.2 cell line has constitutively actived NFAT2, NFAT2 and NFAT4 species; Figure S2: RT-PCR of transcripts modulated by 24 hour treatment with CSA; Figure S3: CNPIs do not modulate KIT signaling and KIT inhibitors do not affect NFAT loca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e518f583acccdf8a901bb064a3d220b
https://doi.org/10.1158/1535-7163.22500676
https://doi.org/10.1158/1535-7163.22500676
Autor:
Sebastian Bauer, Jonathan A. Fletcher, Stefan Fröhling, Peter Hohenberger, Peter Horak, Benedikt Brors, Albrecht Stenzinger, Hanno Glimm, Hans-Ulrich Schildhaus, Thomas Herold, Stefanie Bertram, Karl Worm, Jürgen Treckmann, Eva Wardelmann, Wolfgang Hartmann, Marcel Trautmann, Adrian Marino-Enriquez, Susanne Grunewald, Michael C. Heinrich, Julia Ketzer, Thomas Mühlenberg
Sporadic gastrointestinal stromal tumors (GIST), characterized by activating mutations of KIT or PDGFRA, favorably respond to KIT inhibitory treatment but eventually become resistant. The development of effective salvage treatments is complicated by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23adb7dca5bd417d759dcce3066cef7d
https://doi.org/10.1158/1535-7163.c.6539607
https://doi.org/10.1158/1535-7163.c.6539607
Autor:
Sebastian Bauer, Michael C. Heinrich, Daniel Rauh, Oleg Schmidt-Kittler, Stephen Miller, Paul Czodrowski, Sascha Jung, Jonathan A. Fletcher, Juergen Treckmann, Hans-Ulrich Schildhaus, Wolfgang Hartmann, Eva Wardelmann, Christiane Ehrt, Ajia Town, Johanna Falkenhorst, Jonas Lategahn, Thomas Mühlenberg, Lillian R. Klug, Susanne Grunewald
Gastrointestinal stromal tumors (GIST) harboring activating mutations of PDGFRA respond to imatinib, with the notable exception of the most common mutation, D842V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b3f20d7693dc0c2d93617aad750144e
https://doi.org/10.1158/2159-8290.c.6548281.v1
https://doi.org/10.1158/2159-8290.c.6548281.v1
Autor:
Kathleen M. Sakamoto, Keith B. Glaser, Michael C. Heinrich, Diana Griffith, Ajia Presnell, Xiaolin Tan, Elliot M. Landaw, Joan P. Zape, Jenny E. Hernandez-Davies
Supplementary Figure 3 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05a7ee63525783ac9a81acbdd140aaf0
https://doi.org/10.1158/1535-7163.22496235.v1
https://doi.org/10.1158/1535-7163.22496235.v1